---
figid: PMC4091046__fimmu-05-00304-g004
figlink: /pmc/articles/PMC4091046/figure/F4/
number: F4
caption: Intervention in pathophysiological conditions by modulating the adenosine-A2AR
  pathway. Enhancement of the adenosine-mediated immunosuppression can be done by
  directly stimulating A2AR using agonists or by increasing adenosine levels using
  CD39/73 inducer or inhibitors of nucleoside transporter, adenosine deaminase, and
  adenosine kinase. This treatment should alleviate various inflammatory disorders.
  Conversely, weakened adenosine-dependent immunosuppression is expected to enhance
  anti-pathogen immune response. This modulation will be possible by inhibiting extracellular
  adenosine production (CD39/73 inhibitor), by enhancing adenosine degradation (adenosine
  deaminase), or by blocking adenosine binding to A2AR (antagonists).
pmcid: PMC4091046
papertitle: Extracellular Adenosine-Mediated Modulation of Regulatory T Cells.
reftext: Akio Ohta, et al. Front Immunol. 2014;5:304.
pmc_ranked_result_index: '30804'
pathway_score: 0.5120508
filename: fimmu-05-00304-g004.jpg
figtitle: Intervention in pathophysiological conditions by modulating the adenosine-A2AR
  pathway
year: '2014'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4091046__fimmu-05-00304-g004.html
  '@type': Dataset
  description: Intervention in pathophysiological conditions by modulating the adenosine-A2AR
    pathway. Enhancement of the adenosine-mediated immunosuppression can be done by
    directly stimulating A2AR using agonists or by increasing adenosine levels using
    CD39/73 inducer or inhibitors of nucleoside transporter, adenosine deaminase,
    and adenosine kinase. This treatment should alleviate various inflammatory disorders.
    Conversely, weakened adenosine-dependent immunosuppression is expected to enhance
    anti-pathogen immune response. This modulation will be possible by inhibiting
    extracellular adenosine production (CD39/73 inhibitor), by enhancing adenosine
    degradation (adenosine deaminase), or by blocking adenosine binding to A2AR (antagonists).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ENTPD1
  - NT5E
  - Istradefylline
  - Regadenoson
  - Adenosine
  - Caffeine
  - Dipyridamole
  - Methotrexate
  - Nucleoside
  - Sulfasalazine
  - Theophylline
  - Pentostatin
genes:
- word: CD39/73inducerAdenosine
  symbol: CD39
  source: hgnc_prev_symbol
  hgnc_symbol: ENTPD1
  entrez: '953'
- word: CD39/73
  symbol: CD73
  source: hgnc_alias_symbol
  hgnc_symbol: NT5E
  entrez: '4907'
chemicals:
- word: Istradefylline
  source: MESH
  identifier: C111599
- word: Regadenoson
  source: MESH
  identifier: C430916
- word: Adenosine
  source: MESH
  identifier: D000241
- word: Caffeine
  source: MESH
  identifier: D002110
- word: Dipyridamole
  source: MESH
  identifier: D004176
- word: Methotrexate
  source: MESH
  identifier: D008727
- word: Nucleoside
  source: MESH
  identifier: D009705
- word: Sulfasalazine
  source: MESH
  identifier: D012460
- word: Theophylline
  source: MESH
  identifier: D013806
- word: Pentostatin
  source: MESH
  identifier: D015649
diseases: []
figid_alias: PMC4091046__F4
redirect_from: /figures/PMC4091046__F4
figtype: Figure
---
